Recent advances in the treatment of non-small cell and small cell lung cancer

F1000Prime Reports

Volumn 6, Issue , 2014, Pages

  Stinchcombe, Thomas E ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; AZD 9291; BEVACIZUMAB; CERITINIB; CISPLATIN; CRIZOTINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; HM 61713; NECITUMUMAB; PEMETREXED; PLACEBO; RAMUCIRUMAB; ROCILETINIB; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; DRUG EFFICACY; EXON; GENE MUTATION; GENE REARRANGEMENT; HUMAN; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POINT MUTATION; PROGRESSION FREE SURVIVAL; SMALL CELL LUNG CANCER; TREATMENT RESPONSE;

EID: 84919385796     PISSN: 20517599     EISSN: 20517599     Source Type: Journal    
DOI: 10.12703/P6-117     Document Type: Article

References (21)

1. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger S, Cosper AK, Akhavanfard S, Heist RS, Temel J, Christensen JG, Wain JC, Lynch TJ, Vernovsky K, Mark EJ, Lanuti M, Iafrate AJ, Mino-Kenudson M, Engelman JA: Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011, 3:75ra26.
2. Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, Kris MG, Miller VA, Ladanyi M, Riely GJ: Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 2013, 19:2240-7.
3. Zhou W, Ercan D, Chen L, Yun CH, Li D, Capelletti M, Cortot AB, Chirieac L, Iacob RE, Padera R, Engen JR, Wong KK, Eck MJ, Gray NS, Jänne PA: Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 2009, 462:1070-4.
4. Janne PA, Ramalingam SS, Yang JC-H, Ahn M-J, Kim D-W, Kim S-W, Planchard D, Ohe Y, Felip E, Watkins C, Cantarini M, Ghiorghiu S, Ranson M: Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor-resistant non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol 2014, 32:s5.
5. Sequist LV, Soria J-C, Gadgeel SM, Wakelee HA, Camidge DR, Varga A, Solomon BJ, Papadimitrakopoulou V, Jaw-Tsai SS, Caunt L, Kaur P, Rolfe L, Allen AR, Goldman JW: First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M) [abstract]. J Clin Oncol 2014, 32:s5.
6. Kim D-W, Lee DH, Kang JH, Park K, Han J-Y, Lee J-S, Jang I-J, Kim H-Y, Son J, Kim J-H: Clinical activity and safety of HM61713, an EGFRmutant selective inhibitor, in advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations who had received EGFR tyrosine kinase inhibitors (TKIs) [abstract]. J Clin Oncol 2014, 32:s5.
7. Pennell NA, Neal JW, Chaft JE, Azzoli CG, Janne PA, Govindan R, Evans TL, Botelho Costa D, Greenerger Rosovsky RP, Wakelee HA, Suk Heist R, Tsang Shaw A, Temel JS, Shapiro MA, Muzikansky A, Lanuti M, Lynch TJ, Kris MG, Sequist LV: SELECT: A multicenter phase II trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC [abstract]. J Clin Oncol 2014, 32:s5.
8. Kelly K, Altorki NK, Eberhardt WEE, O'Brien MER, Spigel DR, Crino L, Tsai C-M, Kim J-H, Kyung Cho E, Szczesna A, Burghuber O, Hoffman PC, Keshavjee S, Orlov S, Serwatiwski P, Wang J, Foley MA, Horan JD, Park JW, Shepherd FA, The Tarceva Radiant Investigator Group: A randomized, double-blind phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection with or without adjuvant chemotherapy in patients (pts) with stage IB-IIIA EGFR positive (IHC/FISH) non-small cell lung cancer (NSCLC): RADIANT results [abstract]. J Clin Oncol 2014, 32:s5.
9. Abrams J, Conley B, Mooney M, Zwiebel J, Chen A, Welch JJ, Takebe N, Malik S, McShane L, Korn E, Williams M, Staudt L, Doroshow J: National Cancer Institute's Precision Medicine Initiatives for the New National Clinical Trials Network. Am Soc Clin Oncol Educ Book 2014, 34:71-6.
10. Yang JC-H, Sequist LV, Schuler MH, Mok T, Yamamoto N, O'Byrne KJ, Hirsh V, Geater SL, Zhou C, Massey D, Zazulina V, Wu Y-L: Overall survival (OS) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut): Pooled analysis of two large open-label phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6]) comparing afatinib with chemotherapy (CT) [abstract]. J Clin Oncol 2014, 32:s5.
11. Riely GJ, Pao W, Pham D, Li AR, Rizvi N, Venkatraman ES, Zakowski MF, Kris MG, Ladanyi M, Miller VA: Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 2006, 12:839-44.
12. Jackman DM, Yeap BY, Sequist LV, Lindeman N, Holmes AJ, Joshi VA, Bell DW, Huberman MS, Halmos B, Rabin MS, Haber DA, Lynch TJ, Meyerson M, Johnson BE, Jänne PA: Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 2006, 12:3908-14.
13. Kato T, Seto T, Nishio M, Goto K, Atagi S, Hosomi Y, Yamamoto N, Hida T, Maemindo M, Nakagawa K, Nagase S, Okamoto I, Yamanaka T, Harada R, Kukuoka M, Yamamoto N: Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation-positive nonsquamous non-small cell lung cancer (NSCLC): An open-label randomized trial [abstract]. J Clin Oncol 2014, 32:s5.
14. Mok TS, Kim D-W, Wu Y-L, Solomon BJ, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Tursi J, Blackhall FH: Firstline crizotinib versus pemetrexed-cisplatin or pemetrexed-carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014) [abstract]. J Clin Oncol 2014, 32:s5.
15. Shaw AT, Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, Riely GJ, Solomon BJ, Wolf J, Thomas M, Schuler M, Liu G, Santoro A, Lau YY, Goldwasser M, Boral AL, Engelman JA: Ceritinib in ALKrearranged non-small-cell lung cancer. N Engl J Med 2014, 370:1189-97.
16. Kim D-W, Mehra R, Tan DS-W, Felip E, Quan Man Chow L, Camidge DR, Vansteenkiste JF, Sharma S, De Pas T, Riley GJ, Solomon BJ, Wolf J, Thomas M, Schuler MH, Liu G, Santoro A, Geraldes M, Boral A, Yovine AJ, Tsang Shaw A: Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): Results of the ASCEND-1 trial [abstract]. J Clin Oncol 2014, 32:s5.
17. Thatcher N, Hirsch FR, Szczesna A, Ciuleanu T-E, Szafranski W, Dediu M, Ramlau R, Galiulin R, Bálint B, Losonczy G, Kazarnowicz A, Park K, Schumann C, Reck M, Paz-Ares M, Depenbrock H, Nanda S, Kruljac-Letunic A, Socinski MA: A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) chemotherapy plus necitumumab (IMC-11F8/LY3012211) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC) [abstract]. J Clin Oncol 2014, 32:s5.
18. Perol M, Ciuleanu T-E, Arrieta O, Prabhash K, Syrigos KN, Göksel T, Park K, Kowalyszyn RD, Pikiel J, Czyzewicz G, Orlov S, Lewanski CR, Alexandris E, Zimmerman A, Chouaki N, John WJ, Yurasov S, Garon EB: REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line treatment of stage IV non-small cell lung cancer (NSCLC) following disease progression after one prior platinum-based therapy [abstract]. J Clin Oncol 2014, 32:s5.
19. Slotman B, Faivre-Finn C, Kramer G, Rankin E, Snee M, Hatton M, Postmus P, Collette L, Musat E, Senan S; EORTC Radiation Oncology Group and Lung Cancer Group: Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 2007, 357:664-72.
20. Seto T, Takahashi T, Yamanaka T, Harada H, Nokihara H, Saka H, Nishio M, Nakagawa K, Takayama K, Ishimoto O, Takeda K, Yoshioka H, Tachihara M, Sakai H, Goto K, Yamamoto N: Prophylactic cranial irradiation (PCI) has a detrimental effect on the overall survival (OS) of patients (pts) with extensive disease small cell lung cancer (ED-SCLC): Results of a Japanese randomized phase III trial [abstract]. J Clin Oncol 2014, 32:s5.
21. Slotman BJ, Faivre-Finn C, Tinteren Hv, Praag J, Knegjens J, El Sharouni S, hatton M, Keijser A, Senan S: Randomized trial on thoracic radiotherapy (TRT) in extensive-stage small cell lung cancer [abstract]. J Clin Oncol 2014, 32:s5.